Related Experiment Videos
Pleconaril, a novel antipicornaviral agent
Naomi R Florea1, Dana Maglio, David P Nicolau
1Department of Pharmacy Research, Hartford Hospital, Hartford, Connecticut 06102, USA.
Pharmacotherapy
|March 12, 2003
Summary
No specific antiviral treatments exist for Picornaviridae infections like rhinoviruses. Pleconaril, a new oral antiviral, shows promise for treating these respiratory and serious infections effectively.
Area of Science:
- Virology
- Pharmacology
- Drug Development
Background:
- Picornaviridae family viruses, including rhinoviruses and enteroviruses, lack specific antiviral therapies.
- Structural studies of picornaviruses in the 1980s enabled the development of targeted antiviral compounds.
Purpose of the Study:
- To evaluate Pleconaril, a novel orally available antiviral agent, for the treatment of picornaviral infections.
Main Methods:
- Characterization of Pleconaril's pharmacokinetics using a two-compartment open model with first-order absorption.
- Assessment of Pleconaril's safety profile compared to placebo.
Main Results:
- Pleconaril demonstrated a safety profile comparable to placebo.
- Promising efficacy was observed in treating picornaviral respiratory tract infections and meningitis.
Conclusions:
- Pleconaril is a promising systemically acting antiviral agent for picornaviral infections.
- Further investigation into Pleconaril for various picornaviral infections, including life-threatening ones, is warranted.